Faex Health launches fundraising round to expand U.S. health plan growth

By AI, Created 8:16 AM UTC, May 28, 2026, /AGP/ – Faex Health has opened a fundraising round to back expansion with U.S. health plans and employers, while also pursuing government and healthcare-system partnerships abroad. The company is leaning on a first enterprise customer, a Chile hospital trial and an Africa cholera pre-screening initiative to support its pitch to investors.

Why it matters: - Faex Health is trying to turn AI-powered digestive-health screening into a bigger commercial business with health plans and employers. - The company is also using the round to push into public-health partnerships in South America and Africa, where GI disease burden remains high. - The fundraising could help Faex expand clinical validation, which is often a key hurdle for health tech tools aimed at payers and governments.

What happened: - Faex Health announced the launch of a fundraising round to support expansion across U.S. health plans, employer markets and international public-health initiatives. - The company is engaging strategic investors, healthcare partners and venture firms. - Faex plans to use the capital to expand payer and employer go-to-market efforts in the U.S., invest in clinical studies and product development, and build government and healthcare-system partnerships in priority international markets. - The company’s platform uses smartphone-based stool image analysis and artificial intelligence to help users monitor digestive-health patterns and receive real-time gastrointestinal insights, including pre-screening for 16 GI conditions. - Faex Health’s products are available on Apple’s App Store and Google Play.

The details: - In May 2026, Faex announced its first enterprise customer: an employee health plan serving more than 50,000 employees. - On May 18, 2026, Faex announced a clinical validation trial with Hospital Dr. Sótero del Río in Chile. - The Chile trial is evaluating whether smartphone-based stool analysis can help identify patients at elevated risk for colorectal abnormalities while they wait for colonoscopy. - Earlier in May, Faex announced a cholera-focused pre-screening initiative aimed at expanding healthcare accessibility in Africa. - Faex is a Colorado-based health technology company focused on AI-powered tools for digestive-health monitoring and early disease awareness.

Between the lines: - Faex is building a case that its technology can work in both commercial and public-health settings. - The company is pointing to large addressable markets to support its fundraising pitch, including employer-sponsored insurance and public programs in the U.S. - Citing KFF, employer-sponsored insurance covers more than 150 million Americans, while Medicaid and CHIP enrollment exceeded 75 million individuals in early 2026. - Globally, colorectal cancer and infectious gastrointestinal diseases remain major public-health problems, especially in underserved regions. - CEO Landon Nattrass said the round will help Faex accelerate execution across health plans, strengthen clinical validation and expand access to scalable gastrointestinal health tools.

What’s next: - Faex will continue talking with investors, healthcare partners and venture firms as it seeks to close the round. - The company is expected to keep pursuing payer and employer deals in the U.S. - Faex is also working on clinical studies and partnership development in target international markets. - The company’s future growth will likely depend on whether it can convert early pilots and validation work into broader adoption.

The bottom line: - Faex Health is using a fresh fundraising push to bridge two markets at once: U.S. payer growth and global public-health deployment.